STRESSEconomicGlobal
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Published:
News summary
ORZEYFULTM approved in the U.S., Japan and China for narcolepsy type 1 (NT1), MIMRYLOTM launched in the U.S. for erythrocytosis in polycythemia vera (PV) Zasocitinib advances to U.S.
- Importance
- Low · 23/100
- Impact direction
- Positive